High-risk (HR) multiple myeloma (MM) has poor outcomes with conventional therapy. Tandem autologous-non-myeloablative (NMA) allogeneic stem cell transplantation (autologous stem cell transplantation (ASCT)-NMA allogeneic SCT) is potentially curative secondary to graft-versus-myeloma effect. We retrospectively analysed ASCT-NMA allogeneic SCT outcomes of 59 HR and relapsed MM patients. At a median follow-up of 35.8 months, the outcomes for HR-MM upfront tandem ASCT-NMA allogeneic SCT and standard-risk (SR) MM upfront ASCT alone were comparable (median PFS 1166 days versus 1465 days, P = 0.36; median overall survival (OS) not reached in both cohorts, P = 0.31). The 5-year PFS and OS of patients who had ASCT-NMA allogeneic SCT after relapsing from previous ASCT were 30% and 48% respectively. High CD3+ cell dose (43 × 10 8 /kg) infusion was associated with more acute GvHD (grade 2-4) (47% vs 17.5%; P = 0.03), extensive chronic GvHD (80% vs 50%; P = 0.04), increased transplant-related mortality (26.3% vs 5%; P = 0.009) and inferior OS (median OS 752 days vs not reached; P = 0.002). On multivariate analysis, response achieved with tandem transplant ( oCR vs CR vs stringent CR; hazard ratio = 5.54, confidence interval = 2.67-11.5; P o0.0001) and CD3+ cell dose infused (hazard ratio = 1.42; confidence interval = 1.21-1.67; P o 0.0001) emerged as factors influencing OS. We conclude that tandem ASCT-NMA allogeneic SCT is an effective therapy for HR or relapsed MM and that higher CD3+ doses have an adverse impact on transplant outcome.
INTRODUCTION
Multiple myeloma (MM) is a malignant plasma cell disorder predominantly of the elderly considered to be incurable with currently available pharmacotherapeutic approaches. This fact notwithstanding, the past decade has witnessed remarkable progress in our understanding of the biology of the disease and the development of a variety of newer therapies, including immunomodulators (IMIDs) and proteasome inhibitors (PIs) , that are effective in treating MM. [1] [2] [3] [4] Current treatment modalities, including combinations of IMIDs and PIs, and autologous stem cell transplantation (ASCT) produce longer and deeper responses, but patients will eventually relapse with progressive disease. The management of relapsed MM is challenging particularly in those who become refractory to IMIDs and PIs. 5, 6 Furthermore, a subgroup of patients with high-risk (HR) features at diagnosis manifest aggressive disease at onset with only short-term or no response to these newer therapies. 7 The International Myeloma Working Group (IMWG), with their combined geneticsInternational Staging System (ISS) stage risk stratification model, has demonstrated that the 20% of newly diagnosed patients with HR MM have a median overall survival (OS) of only 2 years. 8 Allogeneic transplantation is a potential therapeutic option for HR and relapsed MM with a recent consensus paper recommending this approach for suitable patients at first relapse, particularly those harbouring adverse biological diagnostic features and/or suboptimal responses to accepted first-line therapies. 9 Previous studies have clearly shown a graft-versus-myeloma effect in a subset of patients following allogeneic transplantation, but early experiences with myeloablative conditioning regimens were associated with unacceptably high rates of transplant-related mortality (TRM). [10] [11] [12] [13] [14] [15] [16] Subsequently, approaches utilising reducedintensity conditioning or non-myeloablative (NMA) conditioning demonstrated considerably reduced TRM but with high relapse rates. 17, 18 An approach that has more recently been evaluated is a tandem transplant procedure combining ASCT followed by NMA allogeneic transplantation to achieve robust control of the MM and then to promote a graft-versus-myeloma effect active against residual MM. We have performed tandem ASCT-NMA allogeneic transplantation for HR and relapsed MM patients at our centre since 2008 and have now undertaken a retrospective analysis to evaluate patient outcomes and the factors influencing those outcomes.
MATERIALS AND METHODS
Between May 2008 and June 2015, a subset of patients referred to the Alfred Hospital, Melbourne, Australia, with MM underwent either an 'upfront' or 'deferred' tandem ASCT-NMA allogeneic transplantation procedure as part of their disease management. The patients were identified from review of hospital medical records. Informed consent was obtained from all patients. The decision for upfront tandem transplantation was based on the presence of at least 2 of 5 HR features: ISS score III, adverse cytogenetics (t(4;14 and/or 17p − identified on FISH and/or complex karyotype on metaphase analysis), elevated lactate dehydrogenase, plasma cell leukemia (all at diagnosis) or induction failure (less than PR) with PI-or IMID-based combination chemotherapy. All patients received at least three cycles of induction treatment before tandem transplantation. The patients who did not fall into the HR category were labelled as having standard risk (SR) and for those up to the age of 70 years were treated with PI-or IMID-based combination chemotherapy followed by upfront ASCT alone. Deferred tandem ASCT-NMA allogeneic transplantation was offered to patients who relapsed after conventional upfront treatment with ASCT. These patients must have achieved at least a PR with salvage treatment before consideration of deferred tandem transplantation.
Conditioning for all ASCT was high-dose melphalan (200 mg/m 2 ). After haematopoietic recovery post ASCT, with no evidence of infection or mucositis, patients underwent NMA allografting conditioned with oral fludarabine 48 mg/m 2 daily from day − 4 to day − 2 and TBI (2 Gy) on day 0. This was followed by infusion of stem cells from HLA-matched sibling or unrelated donors. Target stem cell dose was 2 × 10 6 CD34 + cells/kg. Cyclosporine and mycophenolate mofetil were used as GvHD prophylaxis. Anti-infective prophylaxis included ciprofloxacin during the neutropenic phase (neutrophils o 1.0 × 10 9 /L) and trimethoprim-sulfamethoxazole and valacyclovir for Pneumocystis jiroveci pneumonia and Varicella zoster prophylaxis, respectively, for 12 months. No routine fungal or CMV prophylaxis was used. All patients were monitored for CMV reactivation with weekly CMV quantitative PCR testing and followed up in the day care unit or transplant clinic at least weekly for the first 3 months after transplantation to monitor treatment-related complications. Chimerism analysis was performed monthly for the first 3 months, and then 3 monthly for the remainder of the first year and more frequently in case of mixed chimerism. A singleplex PCR amplification of STR markers was used for analysis. 19 Patients with ⩾ 95% donor-specific chimerism were considered as having complete donor chimerism, whereas those with o95% were considered as incomplete or mixed donor chimerism.
Disease response evaluation post transplant was performed every 3 months in the first year, every 6 months in the second year and then annually thereafter as per the IMWG uniform response criteria. 20 The 8-colour EuroFlow (Beckman Coulter, Brea, CA, USA) MM panel for minimal residual disease (MRD) estimation was introduced in our hospital in November 2014, and since then has been incorporated into the routine post transplant disease evaluation. 21 Statistical analysis PFS and OS were both measured from the time of ASCT. Other outcome measures of specific interest were the incidence of disease progression, TRM, acute GvHD and chronic GvHD. Both PFS and OS were calculated using the method of Kaplan-Meier and comparisons were done by logrank test. TRM was a competing risk for estimating cumulative incidences of disease progression and GvHD. The covariates included in the univariate analysis were age at ASCT, gender, ISS stage at diagnosis (stage 3 versus 1 or 2), number of prior lines of treatment (1-3 versus 43), disease status at allogeneic SCT (⩾ very good partial remission (VGPR) versus oVGPR), timing of tandem transplant (upfront versus deferred), donor type (sibling versus matched unrelated), CD34 + cell dose infused during allotransplant, CD3+ cell dose infused during allotransplant and best response achieved with tandem transplant (stringent CR versus CR versus o CR). Covariates found statistically significant in univariate analysis were used to perform multivariate analysis. Hazard ratios and confidence intervals in univariate and multivariate analyses for PFS and OS were estimated by Cox proportional hazard regression method and multivariate analysis for risk of progression performed by competing risk regression method. Multiple imputations with boot strapping method were used for the missing data in two covariates before finding out the best parsimonious model with Bayesian information criterion. Statistical analysis was performed utilising R version 3.1.0 (R Foundation for Statistical Computing, Vienna, Austria).
RESULTS
Patient characteristics and outcomes after a median follow-up of 48.3 months are given in Table 1 . All patients received allogeneic transplantation as planned following ASCT and all engrafted. Unrelated stem cell donors were used for 60% of the patients. Severe neutropenia (o 0.5 ×10 9 /L) or thrombocytopenia (o 20 × 10 9 /L) post allograft occurred in 56% and 7% of patients, Abbreviations: ASCT = autologous stem cell transplantation; HSCT = haematopoietic stem cell transplantation; IMID = immunomodulator; ISS = International Staging System; LDH = lactate dehydrogenase; Neu = neutrophil; NMA = non-myeloablative; Plat = platelet; PI = proteasome inhibitor; pts, patients.
Impact of donor CD3+ cell dose on HR myeloma outcome AP Nair et al respectively. Of the 59 patients, 51 (86%) received their allografts as outpatients. Of these 51 patients, 29 (49%) required hospitalisation in the first month following transplant, predominantly for the management of febrile illnesses or acute GvHD. Of the 59 patients, 27 (46%) achieved full donor chimerism by day 30 and all patients achieved full donor chimerism by 1 year. Cumulative incidences of both acute and chronic GvHD did not significantly differ between upfront and deferred cohorts or between sibling and unrelated donor transplant recipients. Proportions of patients who required any form of ongoing anti-GvHD treatment at the end of 1, 2 or 3 years post-tandem transplant were 61%, 50% and 44%, respectively. The PFS and OS of patients who had adverse cytogenetic risks (t(4;14) and/or 17p − and/or complex karyotype) did not differ significantly from the remainder of the patients within the tandem transplant cohort (median PFS = 458 days versus 762 days, P-value = 0.09; median OS = 897 days versus 1389 days, P-value = 0.7, respectively). When the analysis was restricted to the deferred tandem transplant cohort outcome was significantly related to the number of prior lines of therapy, where patients who had received 43 prior lines had significantly inferior outcomes compared with those with 1-3 prior lines (PFS at 5 years = 9.4% versus 78.6%, P-value = 0.0001; OS at 5 years 37.31% versus 77.38%, P-value = 0.03, respectively).
We then compared the survival of HR MM patients undergoing upfront tandem transplantation with the outcomes of 57 contemporaneous consecutive patients receiving ASCT alone for SR MM. Baseline characteristics of these groups and their outcomes are illustrated in Supplementary Table 1. The median age of the HR group was 52 years and that of the SR group was 60 years (P = o 0.0001). The median follow-up time was 35.8 months. The two groups demonstrated comparable PFS and OS ( Figure 1 ). To avoid any age bias, we then compared the outcomes between 27 younger SR MM patients who received ASCT alone and 25 HR MM patients, matched for median age, who underwent upfront tandem auto-NMA allogeneic transplantation during the same period (Supplementary Table 1 ). The median age of both cohorts was 53 years and both groups demonstrated similar survival (Figure 1) .
Within the whole tandem ASCT-NMA allogeneic transplant cohort we then undertook an analysis to identify factors influencing outcome. Factors on univariate analysis that influenced PFS and OS are illustrated in Supplementary Table 2 . Number of prior lines of treatment, disease status at the time of allogeneic transplantation and best response achieved following transplantation were significantly associated with PFS, whereas ISS stage, donor CD3+ cell dose infused and best response achieved following tandem transplantation emerged as factors significantly associated with OS. Factors with significant influence on the cumulative incidence of progression were best response achieved with tandem transplant ( oCR vs CR vs stringent CR = 74.4% vs 42.2% vs 14.3% respectively at 5 years; P = 0.001), status at allogeneic transplantation ( oVGPR vs ⩾ VGPR = 74.7% vs 27.1% respectively at 5 years; P = 0.003), timing of transplantation (deferred vs upfront = 62.3% vs 36.7% respectively at 5 years; P = 0.03) and number of prior line of treatment (43 vs 1-3 = 78.1% vs 35.7% respectively at 5 years; P = 0.001).
Results of a multivariate analysis of factors influencing survival and progression are given in Table 2 . Response achieved with tandem transplantation emerged as the most important factor on multivariate analysis affecting all transplant outcomes. Interestingly, donor CD3+ cell dose infused, when used as a continuous variable, had a significant adverse impact on OS. /kg as having the greatest adverse impact on OS with a hazard ratio of 3.8 (confidence interval 1.5-9.4; P = 0.002; Figure 2 ). There were 19 patients in the high CD3 dose arm. The baseline characteristics and outcomes on comparison between patients who received high CD3+ cell dose (43 × 10 8 /kg) and low CD3 dose (⩽3 × 10 8 / kg) at the time of stem cell infusion are illustrated in Table 3 . Achievement of donor CD3 chimerism when compared between the two CD3+ cell dose arms at different time points (days 30, 60, 90 and 180) revealed no significant difference. There was significant difference between the groups in incidences of grade 2-4 acute and extensive chronic GVHD, but this did not make any impact on myeloma relapse.
EuroFlow MRD assessment demonstrated MRD negativity in 21 of 30 patients tested in a median follow-up of 31.3 months. Of the 12 recently transplanted patients, 4 patients who have had sequential MRD assessment from 3 months post transplant demonstrated conversion from MRD positivity at 3 months to negativity at 6 months post transplant.
DISCUSSION
Despite significant advances in the management of MM, the disease remains incurable. Driven by the marked heterogeneity in the clinical behaviour of the disease, a variety of prognostic factors have been identified including age, cytogenetics, tumour burden, circulating plasma cells and lactate dehydrogenase. [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] Subsequently, risk models combining different individual risk factors have been developed that have defined HR MM patients who respond poorly to conventional therapies. Both the IMWG and Medical Research Council in their independent studies showed that the combination of high ISS stage and adverse cytogenetics is associated with inferior survival. 8, 35 A recent German study showed 5-year survival of 41% in a relatively younger HR MM cohort treated with induction therapy followed by upfront ASCT. 36 More recently, the Revised ISS (R-ISS) incorporating adverse chromosomal abnormalities, high lactate dehydrogenase and ISS stage has been published. 37 The R-ISS was derived from an analysis of 3060 newly diagnosed MM patients, predominantly treated with newer generation anti-MM drug combinations (IMIDs and/or PIs) and demonstrated that patients with R-ISS stage-3 disease (ISS stage-3 plus high-risk chromosomal abnormality and/or high lactate dehydrogenase) have a particularly poor outcome (5-year PFS of 24% and 5-year OS of 40%).
In contrast, our study shows comparable outcomes for HR MM patients treated with upfront tandem transplantation and SR MM patients receiving conventional front-line therapy including ASCT, suggesting that this strategy may be able to abrogate the impact of the adverse biological features of HR MM. Furthermore, PFS and OS were comparable when matching the HR and SR cohorts for age. Importantly, a plateauing of the tandem cohort PFS curve after 3 years may indicate that a proportion of these HR MM patients may experience prolonged disease control or perhaps cure. This possibility is further supported by the attainment of EuroFlow MRD negativity in more than one-third of patients analysed to date, as previous studies have clearly documented that achievement of MRD negativity post therapy is associated with a significantly positive impact on outcome. [38] [39] [40] The conversion to MRD negativity at 6 months post transplantation in four patients is evidence of a clinically relevant graft-versusmyeloma effect.
Previous studies have examined the role of tandem transplant approaches in newly diagnosed MM and a number of studies have compared tandem auto-NMA allogeneic transplantation with tandem ASCT. [41] [42] [43] [44] [45] In these studies, patient allocation to the allogeneic transplantation arms was determined by the availability of a matched donor and none has specifically evaluated the utility of allografting in patients defined as HR incorporating contemporary definitions of disease risk. For example, in both the IFM99 and BMTCTN trials, the patients were considered to have HR MM if they had an elevated b2 microglobulin or deletion of Abbreviations: CI = confidence interval; HR = hazard ratio; ISS = International Staging System; NMA = non-myeloablative; OS = overall survival; SCT = stem cell transplantation. chromosome 13 and did not include any of the chromosomal or nonchromosomal features that we have used to stratify our patients. 42, 43 Similarly, the HOVON study used the same criteria but also evaluated differences in outcome based on ISS stage. 44 This study demonstrated a trend towards improved survival for HR patients following auto-allo-transplantation when compared with tandem ASCT, but the difference was not significant, perhaps because of the small number of patients studied. Another confounding factor is that different studies have utilised different conditioning approaches for allogeneic transplantation. The HOVON and BMTCTN studies used low-dose TBI alone for conditioning, whereas the IFM group used busulfan, fludarabine and in vivo T-cell depletion with anti-thymocyte globulin. However, the study from European Society for Blood and Marrow Transplantation (EBMT) group, which demonstrated a significant improvement in OS after upfront tandem auto-allotransplantation compared with upfront single or tandem ASCT, used the same conditioning regimen as we have used, but again the ability to risk stratify was only based solely on the presence or absence of chromosome 13 deletion. 45 There is a paucity of data on the utility of tandem auto-NMA allotransplantation in relapsed and/or refractory MM. Most studies in the RRMM setting have reported the use of reduced intensity conditioned or NMA allogeneic transplantation without a preceding ASCT procedure and found no benefit when compared with ASCT alone. [46] [47] [48] [49] [50] [51] However, the limited studies that have utilised a tandem approach describe, similar to our experience, that a substantial proportion of patients exhibit long-term remission. 52, 53 The latter observation is consistent with published data demonstrating that patients with better disease control at the time of allografting have superior outcomes compared with patients with active disease at the time of allografting. 50, 54 In concordance with previous reports, we also found that attaining a deeper response with therapy was associated with a superior outcome. 40, [55] [56] [57] [58] This was true regardless of whether response assessment was before or after the NMA allotransplant. All the patients who achieved stringent CR after allografting are alive and only one of them has progressed. Moreover, the observation of a higher relapse rate and inferior survival in the deferred transplant group who were heavily pretreated supports the importance of offering tandem auto-allo-transplantation earlier rather than later by promptly identifying HR patients earlier in their disease course. 47, 50, 59 Noninferior survival in patients with poor cytogenetic risks within the tandem cohort supports the findings of earlier trials and suggests that allogeneic transplantation may be a way of nullifying the impact of adverse genetics in appropriately selected subgroups of MM. 40, 60 A novel observation in our study is the adverse impact of high donor CD3+ cell dose on survival. The IFM study that utilised in vivo T-cell depletion demonstrated a reduced incidence of GvHD but at the same time an increased relapse rate, resulting in no overall benefit for the allografting approach when compared with ASCT. 42 Hence, although T cell-replete stem cells are generally infused for NMA allogeneic transplants to prevent graft failure and to avail the benefit of a potential graft-versus-tumour effect, our data, although preliminary, suggest that limiting the T-cell inoculum may be beneficial in reducing the risk of deleterious GvHD.
We acknowledge that this is a retrospective study and hence the findings are to be interpreted with caution; however, our data clearly demonstrate that tandem auto-NMA allogeneic transplantation is an effective and safe option to treat selected HR and RR MM with low TRM. We need future studies to explore strategies like limiting T-cell dose and post transplant immunomodulation to further improve patient outcomes. Abbreviations: aGvHD = acute GvHD; ASCT = autologous stem cell transplantation; cGvHD = chronic GvHD; Cum. Incidence = cumulative incidence; NMA = non-myeloablative; OS = overall survival; SCT = stem cell transplantation; TRM = transplant-related mortality.
